Compare Abbott Laboratories (ABT) vs American Well Corp (AMWL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs American Well Corp — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while American Well Corp trades at $8.79 (market cap $150.21M). The key difference: Abbott Laboratories is far larger — about 1111.4× American Well Corp's market cap, and Abbott Laboratories pays a 2.63% dividend while American Well Corp pays none. Which is the better fit depends on your goals.
| ABT | AMWL | |
|---|---|---|
Market Cap | $166.94B | $150.21M |
Sector | Health | Health |
52-Week High | $136.62 | $9.83 |
52-Week Low | $82.57 | $3.78 |
Enterprise Value | $193.69B | -$25.04M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
AMWL trades at $8.99, down 2.81% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows improving financial trends with revenue stabilizing near $249 million in 2025 and net losses narrowing to -$96 million. Recent news highlights momentum, including a Zacks upgrade to Buy on June 24, 2026, and Amazon appointing Amwell's co-founder to lead its healthcare unit on May 27, 2026.
Outlook remains cautious due to persistent losses and negative cash flow, though valuation metrics like P/S of 0.64 and P/B of 0.68 suggest potential upside if profitability improves. Risks include competitive pressures and execution challenges, but analyst consensus leans Hold with a $7.25 price target, indicating limited near-term growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →
